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ARTICLE
Target engagement imaging of PARP inhibitors in
small-cell lung cancer
Brandon Carney1,2, Susanne Kossatz1, Benjamin H. Lok 3,4, Valentina Schneeberger4, Kishore K. Gangangari1,2,
Naga Vara Kishore Pillarsetty 1,5, Wolfgang A. Weber1,4,5, Charles M. Rudin 4,6, John T. Poirier 4,6
& Thomas Reiner 1,5
Insufficient chemotherapy response and rapid disease progression remain concerns for small-
cell lung cancer (SCLC). Oncologists rely on serial CT scanning to guide treatment decisions,
but this cannot assess in vivo target engagement of therapeutic agents. Biomarker assess-
ments in biopsy material do not assess contemporaneous target expression, intratumoral
drug exposure, or drug-target engagement. Here, we report the use of PARP1/2-targeted
imaging to measure target engagement of PARP inhibitors in vivo. Using a panel of clinical
PARP inhibitors, we show that PARP imaging can quantify target engagement of chemically
diverse small molecule inhibitors in vitro and in vivo. We measure PARP1/2 inhibition over
time to calculate effective doses for individual drugs. Using patient-derived xenografts, we
demonstrate that different therapeutics achieve similar integrated inhibition efficiencies
under different dosing regimens. This imaging approach to non-invasive, quantitative
assessment of dynamic intratumoral target inhibition may improve patient care through real-
time monitoring of drug delivery.
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While the diagnosis and treatment of many malignancieshave seen significant improvements over recent dec-ades1, the 5-year survival rates of small-cell lung
cancer (SCLC), a subset of the general lung cancer population
(13%, 29,000 of 221,000 patients in US annually), remain around
5% and are below 1% for the over 60% of patients that are
diagnosed with extensive stage disease. The standard of care for
advanced SCLC has essentially remained stagnant for more than
30 years.
The lack of progress, in part, can be attributed to the aggressive
nature of this disease, which is exceptionally proliferative and
rapidly develops resistance to chemotherapy. Therefore, novel
treatment approaches are needed. Therapeutics that are targeted
against a tumor specific biomarker have gained large interest
because they can specifically act against tumor cells without the
systemic toxicity and side effects of chemo- or radiotherapy. In
the clinical reality, however, only a subset of patients responds
well to targeted therapies. A better understanding of the spatial
distribution and quantification of the target as well as the intra-
tumoral drug-target interaction could strongly improve targeted
therapy approaches by identifying particularly sensitive or resis-
tant patient sub-populations, and by allowing ongoing monitor-
ing of emerging resistance, enabling rapid change in
chemotherapy regimens.
A radiolabelled, non-invasive imaging tracer would be an ideal
candidate for such a diagnostic tool, because it would allow
unlimited “sampling” of all metastases in an individual patient
and provide contemporaneous uptake values, allowing quantita-
tive measurements before, during and after treatment cycles.
One class of therapeutics that are being investigated as new
treatment options for SCLC, are poly ADP-ribose polymerase
(PARP) inhibitors. PARP inhibition, and the associated pertur-
bation of the single-stranded DNA repair pathway, has been
shown to be a promising therapeutic approach in both preclinical
and clinical research settings2. The combination of PARP inhi-
bitors and DNA damaging agents, such as temozolomide, has
seen recent success and sufficient delivery of both drug classes
potentiates their therapeutic effects2,3. One reason for this is that
DNA damage repair plays an important role in the sensitivity of
SCLC to chemotherapeutic agents, and consequently, current
standard of care therapies for SCLC contain at least one DNA
damaging agent. This sensitivity can be attributed in part to the
genetics of this disease: nearly all patients have loss of the tumor
suppressor genes TP53 and RB1, which are critical to the normal
function of multiple DNA damage response pathways and G1/S
checkpoint maintenance, respectively4,5. Critically, there is not
only consistent protein overexpression of PARP1 in SCLC,
but also increased sensitivity to PARP1/2 inhibitors, in spite of
intact BRCA6. On the basis of these observations and the
underlying genetics of the disease, PARP inhibition is gaining
considerable attention as a novel systemic treatment for SCLC
(i.e., NCT02289690, NCT02734004, NCT01286987).
“One-size-fits-all” flat dosing regimens, or weight-based dosing
regimens, have generally been used for members of this drug
class, several of which have advanced to phase III trials. While
this may be sufficient for some clinical applications, many
patients – and in particular SCLC patients–may benefit from an
immediate readout for determining the degree of on-target
intratumoral PARP inhibition and, consequently, an imaging
probe that can monitor and quantify PARP1/2 inhibition success.
In light of the expanding clinical relevance of PARP ther-
apeutics, and the diversity of novel agents in this area, we became
interested in exploring in vivo pharmacodynamic monitoring of
PARP inhibitor target engagement in SCLC. A number of PARP
therapeutics have entered late phase clinical research (talazoparib,
veliparib) or are already FDA approved (olaparib, rucaparib,
niraparib). While all of these small molecules possess unique
pharmacokinetic profiles and therapeutic indices, they share one
common binding motif: the NAD+ active site pocket of PARP.
Therefore, while the development of an imaging tracer for each
individual therapeutic would require considerable preclinical and
clinical resources, we hypothesized that a single imaging tracer
may be used to quantify target engagement for a broad group of
PARP inhibitors, unlike other classes of drugs.
To test this hypothesis, we designed a series of experiments
central to clinical translation of PARP target engagement imaging
that address three fundamental questions: (1) What is the range
of PARP expression in SCLC and will this range support quan-
titative assessment of PARP imaging? (2) Are the putative ima-
ging reagents, [18F]PARPi and PARPi-FL, selective binders of
PARP and do they have the same binding profile as their ther-
apeutic counterparts? (3) Can target inhibition of PARP be
quantified for PARP therapeutics generally and can our PARP
imaging agents non-invasively predict target engagement in vivo?
We believe that finding and validating [18F]PARPi as a widely
applicable, easy-to-use general PARP target engagement imaging
agent is of high value for optimizing SCLC treatment. Such an
agent wouldn’t just serve as a “companion imaging agent” for one
individual molecularly targeted drug, but rather a whole class of
therapeutics, dramatically expanding and amplifying its potential
utility in clinical practice. Here using patient-derived xenograft
















































































































































Fig. 1 Properties of PARP inhibitors. a Structures of 5 clinical therapeutic PARP inhibitors and the 2 PARP imaging agents. b Heatmap visualizing enzymatic
activity screening of 10 small molecules against 12 PARP enzymes at 100 nM concentration (for additional concentrations, see Supplementary Fig. 1)
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technology for quantifying PARP inhibitors and target engage-
ment in vivo in support of the clinical relevance of [18F]PARPi for
treatment monitoring and prediction.
Results
PARP enzyme specificity of inhibitors and imaging agents.
PARP enzymes are a family of 17 proteins that share the same
catalytic PARP domain7. PARP inhibitors have been shown to
exhibit a wide range of pharmacologic specificity within this
family7. For SCLC in particular, upregulation and overexpression
of PARP1 has been demonstrated, and is proposed as a ther-
apeutic target6. In developing PARP targeted imaging agents, we
first wanted to ensure that the modifications made for imaging
did not substantially alter target engagement with the key PARP
enzymes. To determine the specificity of our imaging agents
within this family of enzymes, and to compare their inhibition
profile to clinically relevant PARP therapeutics (Fig. 1a), we
conducted an enzyme activity inhibition screening across all
available enzymes. Included in the study were five inhibitors in
phase III clinical trials or FDA approved: olaparib, veliparib,
talazoparib, niraparib, and rucaparib, together with our imaging
agents [18F]PARPi and PARPi-FL. Besides [18F]PARPi and
PARPi-FL, other PARP imaging agents have been reported in the
literature8 and one of them was recently translated to the clinic9.
We also included AG14361, (Ki(PARP1)< 5 nM)10, UPF1069
(IC50(PARP2) = 0.3± 0.1 µM)11, and iniparib as negative control.
We assessed the inhibitory activities of the PARP therapeutic
agents and our imaging agents across 12 PARP enzymes
including tankyrases TNKS1 and TNKS2 (Fig. 1b, Supplementary
Fig. 1). The imaging agents generally exhibited comparable or
higher specificity for PARP1/2 compared to the therapeutic
molecules. At 100 nM, all therapeutic molecules, except niraparib,
inhibited activity in PARP3 as well as PARP1/2 (>35% for
PARP3, >90% for PARP1 and PARP2). Talazoparib also exhib-
ited inhibition for both tankyrase enzymes, TNKS1 and
TNKS2.19F-PARPi (the non-radioactive analog to [18F]PARPi)
and PARPi-FL showed very low inhibition of TNKS1 and TNKS2
Table 1 Properties of PARP inhibitors
Properties of PARP inhibitors
Olaparib Veliparib Talazoparib Niraparib Rucaparib [18F]PARPi PARPi-FL
MW 434.5 244.3 380.8 320.4 323.4 487.5 640.5
PARP1 IC50 5 nMb 1.2 nMa 0.56 nMa 3.8 nMb 0.65 nMa 2.3 nMb 12.2 nMb
PARP2 IC50 1 nMb 0.41 nMa 0.15 nMa 2.1 nMb 0.08 nMa 0.21 nMa 0.31 nMa
Trappingb ++ + ++++ +++ ++ ND ND
Trials 106 88 20 15 10 0 1
Phase 3 11 6 1 3 1 0 0
a See Supplementary Fig. 2
b Unpublished data13,18,26,29,30
JHU-LX22 JHU-LX108JHU-LX33JHU-LX102 JHU-LX92JHU-LX48 JHU-LX110
JHU-LX88 Lung LiverKidney BrainSpleen Muscle
Fig. 2 PARP expression in PDX lines. PARP1 expression was assessed via immunohistochemistry staining on tissue microarrays (TMAs) in eight PDX lines
which were grown as xenografts in NSG mice and five normal control tissues (spleen, lung, kidney, muscle, liver, and brain). Scale bar represents 200 µm
(whole core) and 20 µm (inset). All PDX lines show high PARP1 expression. All PDX lines are SCLC, except JHU-LX88, which is squamous cell lung cancer.
These tumors showed lower PARP1 expression than all seven SCLC PDX lines and also showed lower expression than spleen, which has a naturally high
PARP1 expression18
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Fig. 3 PARPi-FL blocking and in vitro kinetics of different PARP inhibitors. a JHU-LX22 SCLC cells were treated with 6 different PARP inhibitors, including 5
clinical therapeutic inhibitors and a cold, non-radioactive analog of the PARP PET tracer, [18F]PARPi. Cells were then treated with fluorescent imaging agent
PARPi-FL and either imaged via confocal microscopy or measured via flow cytometry. Microscopy (top) and flow cytometry (bottom) showing reduced
PARPi-FL uptake in all cells treated with PARP inhibitors. b Quantification of PARPi-FL uptake with microscopy (left), flow cytometry (middle) and
correlation between the two (right). c JHU-LX22 cells were incubated with one of 5 PARP inhibitors (olaparib, talazoparib, rucaparib, veliparib, niraparib,
and 19F-PARPi) at a concentration of 0.2 µM for 25min at 37 °C, and washed. After a post-incubation time of 0–48 h, cells were incubated with 0.2 µM
PARPi-FL for 15min at 37 °C, followed by 10min with medium to allow unbound compound to diffuse out of the cells. Then, cells were trypsinized,
subjected to flow cytometry and analyzed for the relative PARPi-FL fluorescence signal. Cells that had not been exposed to a PARP inhibitor served as
control and were defined as 0% relative PARP inhibition. d Decay curves were calculated with Prism using two phase decay least squares regression. Non-
parametric Student’s t-test was used to calculate the statistics. *P< 0.05, **P< 0.01, ***P< 0.001, ****P< 0.001. Error bars represent the SD of three
independent experiments with three parallels each
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(≤5%) and PARP3 (≤30%). Inhibition of PARP1 and PARP2
was strong (both >90%), overlapping with the therapeutic
clinical candidates and providing a rational basis for using our
imaging agents as general sensors for PARP1/2 target engage-
ment. Further comparison of all inhibitors used in this study
(Table 1, Supplementary Fig. 2) showed similar binding affinities
for all inhibitors including the imaging agents, with low
nanomolar IC50 values reported for both PARP1 and PARP2.
[18F]PARPi and PARPi-FL uptake therefore does not reflect
expression of a single enzyme, but it is a sensor for how much
of any tested PARP therapeutic has been retained in a given
tissue, which makes using these imaging agents for target
engagement imaging particularly appealing. This was also
corroborated by the ability of PARPi-FL and [18F]PARPi to
inhibit PARylation, similar to olaparib (Supplementary Fig. 3).
One notable difference is in the trapping ability reported for
each inhibitor, a mode of efficacy whereby the inhibitor traps
the PARP enzyme at the site of DNA damage, leading to
further DNA damage and ultimately cell death12,13. It has been
reported that talazoparib is the most effective PARP trapping
agent14, as well as the most potent PARP inhibitor in SCLC
clinical testing15.
SCLC PDX models show high PARP1 expression levels. In
order to better understand the possible benefit of PARP targeted
therapy and imaging for SCLC, we investigated PARP1
expression in 8 different PDX lines and tissues from 6 different
mouse organs (Fig. 2). Using PARP1 specific antibody staining on
tissue microarrays, we found that all SCLC PDX exhibited ele-
vated PARP1 expression compared to lung, kidney, muscle, liver
and brain. All 7 PDX SCLC lines exhibited greater than 60%
PARP1-positive area (between 64± 6% PARP1-positive area for
JHU-LX92 and 86± 3% PARP1-positive area for JHU-LX102),
while all organs, except for spleen, exhibited lower than 5%
PARP1-positive area (Supplementary Fig. 4), emphasizing the
quantitative difference in PARP1 density for binding of PARP1
targeted agents. Spleen showed higher PARP1 expression than the
other organs, with a 26± 1% PARP1-positive area. The lowest
PARP1 expression was seen in lung squamous cell PDX line,
JHU-LX88, with 18± 6% PARP1-positive area. JHU-LX22 and
JHU-LX48 (subsequently used for in vitro and in vivo studies),
expression was 85± 4% and 78± 6% PARP1-positive area,
respectively.
PARPi-FL is capable of imaging target engagement in vitro.
In order to determine whether we can use PARP1 imaging
agents to probe the characteristics of therapeutic PARP inhibitors,
we first assessed whether the fluorescent PARP imaging
agent, PARPi-FL, is capable of detecting target engagement of a
PARP inhibitor panel in vitro. We tested olaparib, talazoparib,
rucaparib, veliparib and niraparib, as well as 19F-PARPi. Our goal
was to quantify the degree to which PARPi-FL uptake was
reduced by the pretreatment of JHU-LX22 with PARP inhibitors,
denoting how quantitatively the targeted small molecules
occupied the PARP1/2 active site pockets, and, consequently, how
efficiently they blocked available binding sites for PARPi-FL. We
found that all inhibitors were capable of blocking PARPi-FL
uptake, as measured both by confocal microscopy and flow
cytometry (Fig. 3a). Quantitation of the blocking showed that the
most complete target engagement was observed for olaparib,
talazoparib and rucaparib (Fig. 3b). Veliparib, niraparib and
19F-PARPi allowed for slightly more binding of PARPi-FL, but
still blocked more than 50% of the PARPi-FL uptake (Fig. 3b).







































































Fig. 4 In vivo kinetics of [18F]PARPi. JHU-LX48 SCLC PDX bearing mice (n= 3/group, 3 group, 9 mice total) were injected (i.v.) with 200–300 µCi of [18F]
PARPi and imaged via PET/CT at 30, 60, and 120min post injection. a Representative MIPs from a single mouse at all 3 time points. b Quantification of PET
images for tumor and muscle grouped by time point (left) and grouped by organ (right). c Two phase decay curve showing wash out of the tracer from the
muscle as the activity in the tumor site remains relatively constant after 60min (left) along with resulting tumor to muscle ratios (right). Non-parametric
Student’s t-test was used to calculate the statistics. **P< 0.01, ***P< 0.001. Error bars represent the SD
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cytometry and confocal microscopy were in agreement with each
other (Fig. 3b).
Imaging of PARP inhibitor binding kinetics in vitro. Next, we
set out to determine in vitro binding kinetics of the different
inhibitors, and to temporally resolve target engagement for the
individual drugs. Therefore, we measured PARPi-FL uptake
at different time points after PARP inhibitor administration
(0–48 h) using flow cytometry (Fig. 3c). This yields an inverse
measure of the proportion of binding sites still occupied by the
PARP therapeutic. We calculated the target engagement of the
PARP inhibitors by fitting a two phase decay curve to the PARPi-
FL binding curve. Olaparib, talazoparib, rucaparib and 19F-PARPi
showed the longest retention on PARP1/2 binding sites, whereas
veliparib and niraparib showed faster release kinetics (Fig. 3d).
While internally consistent and reproducible, it should be noted
that the estimated half-lives for retention using this in vitro
methodology are a function of the intensity of the washing pro-
cedure, where more intense washing or greater washing medium
volumes will shorten the resulting residence time of the drug and
also affect the amount of residual inhibition at 48 h. This
resembles the in vivo situation, where drugs can experience a
seemingly lower residence time when having been deposited in a
highly perfused tissue. Recovery to full binding of PARPi-FL
could be accelerated by repeated washing (Supplementary Fig. 6)
or dilution of the PARP inhibitor concentration (Supplementary
Fig. 6). Importantly, the relationship between slower and faster
release of drug from the binding sites was consistent across all
experimental settings and corroborated our findings.
We also showed that our imaging data reflects target
engagement, and not differences in affinity, since the small
molecule that first bound to PARP1/2 was dominant at the target
site (Supplementary Fig. 8). Changes toward equilibrium binding
were only observed at longer incubation times (1–2 h), indicating
a slow koff rate. The power and specificity of our approach was
further supported by the fact that iniparib, once thought to be a
PARP inhibitor16,17, failed to reduce PARPi-FL uptake.
We then measured cell viability to determine whether PARPi-
FL and 19F-PARPi displayed toxicities comparable to their
therapeutic counterparts. PARPi-FL and 19F-PARPi showed very
similar effects on JHU-LX22 cell viability as olaparib. Cells were
most sensitive to talazoparib. Veliparib and niraparib, which had
shorter in vitro on-target half-lives than olaparib, talazoparib and
rucaparib, also showed much less cell killing (Supplementary
Fig. 9).
In vivo [18F]PARPi imaging of SCLC PDX models. In order to
map the pharmacokinetics of [18F]PARPi in the JHU-LX48
PDX model, and to identify the time point that provides ideal
tumor/background ratios, we injected tumor bearing mice with
[18F]PARPi and imaged the mice at 30, 60, and 120 min post
injection (Fig. 4a). At 30 min, the tumor was visible above the
background signal of muscle (1.34± 0.28 %ID/g and 0.90± 0.06
%ID/g, respectively), but the differences were not statistically
significant (n = 3, P = 0.1016; Fig. 4b). However, at the 60 min
1 20
%ID/g
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Fig. 5 Tumor size to [18F]PARPi uptake correlation. JHU-LX48 SCLC PDX bearing mice (n= 6) were injected (i.v.) with 200–300 µCi of [18F]PARPi and
imaged. PET/CT imaging was performed once a week over 8 consecutive weeks starting one week after xenografting. a Representative MIPs from the
same mouse over 8 weeks. b Quantification (n= 6) of mean uptake (top) and max uptake (bottom) of the PET images grouped by tumor size. Mean uptake
was calculated to be 0.86 %ID/g across a large range, from 50–1300 mm3, of tumor sizes as quantified from CT VIOs. Small tumor sizes (<50mm3) are
likely affected by partial volume effect19. The figure includes the standard deviation as indicated by the shaded area. Non-parametric Student’s t-test was
used to calculate the statistics. *P< 0.05; **P< 0.01. Error bars represent the SD
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time point, the muscle uptake had begun to clear and activity had
fallen sharply to 0.44± 0.03 %ID/g, while the tumor signal was
retained much more (0.94± 0.04 %ID/g), yielding P = 0.0002
(Fig. 4b). This trend continued to the 120 min time point, with
uptake at 0.12± 0.02 %ID/g for the muscle, while tumor uptake
remained constant at 0.87± 0.21 %ID/g (Fig. 4b). The PARP1/2
imaging agent [18F]PARPi is therefore well suited to image in
PARP1-expressing tumors, quickly clearing from non-target tis-
sue while binding strongly to tumor over the course of 2 h
resulting in a tumor/muscle ratio of 7.6± 2.7 in JHU-LX48
bearing animals (P = 0.0072; Fig. 4c). We also conducted a bio-
distribution study and found differences in organ uptake com-
pared to other immunocompromised mouse models used in
previous studies18 (Supplementary Fig. 5).
[18F]PARPi uptake is similar across tumor sizes. In order to
obtain quantitative data on how tumor size correlates with tracer
uptake, we performed repeated [18F]PARPi imaging studies
in a cohort of JHU-LX48 PDX mice over the course of 8 weeks
(n = 6; Fig. 5a). We evaluated the quantitative performance of the
imaging probe over tumor volumes ranging from <25 mm3 to
>1000 mm3. Once tumors reached a size greater than 50 mm3,
tumor size had no statistically significant effect on the mean
[18F]PARPi signal. Mean signal remained steady at 0.86± 0.22
%ID/g for sizes ranging 50 mm3 to 1300 mm3 with the
highest single value at 1.24 %ID/g and the lowest single value at
0.47 %ID/g (Fig. 5b). Separating the data into groups organized
by tumor size, we observed that at very low tumor volumes
(<50 mm3) uptake values appear lower, presumably because of
the partial volume effect19 and the associated detection limit of
the small animal PET/CT used for these experiments. The highest
mean uptake values (0.97± 0.18 %ID/g) were observed for tumor
sizes between 100 and 200mm3. With larger tumor sizes, mean
signal decreased slightly until reaching a minimum of 0.71± 0.22
%ID/g for tumor sizes between 400 and 800mm3, presumably
due to an increasing fraction of necrotic tissue in larger tumors.
Necrotic tissue does not retain [18F]PARPi, and therefore reduces
the mean uptake. This was confirmed by the maximum uptake
values (Fig. 5b). Organized into groups, the maximum uptake
showed a continuous increase as tumor size increased in this
range, from 2.62± 0.27 %ID/g for 50–100mm3 to 3.06± 0.61
%ID/g for 800–1300 mm3 (Fig. 5b). Maximum uptake across
tumors sizes 50–1300 mm3 was 2.85± 0.49 %ID/g.
Ex vivo autoradiography measurements of target engagement.
In the preclinical setting, olaparib is administered at dosing
levels of 50 mg/kg, whereas talazoparib is used at much lower
doses (e.g., 0.3 mg/kg)20. These trends are also reflected in
the clinical setting (protocols: NCT02032823, NCT02184195,
NCT01945775). Target engagement studies using olaparib and
talazoparib showed that both molecules were capable of reducing
[18F]PARPi signal in tumor and muscle tissue when administered
30 min prior to the tracer (Fig. 6a–c). Using PARP1 IHC staining,
we could show comparably high PARP1 expression in tumors of
all groups, while expression in muscle was very low, confirming
validity of the autoradiography findings (Fig. 6d). Target
engagement was not equivalent for olaparib and talazoparib at
their respective therapeutically active doses. Autoradiography
demonstrated that doses of olaparib were capable of completely
blocking tumor uptake (96% of [18F]PARPi uptake blocked),















































































Fig. 6 Autoradiography. JHU-LX48 SCLC PDX bearing mice (n= 3/group, 3 groups, 9 mice total) were injected either with 200–300 μCi of [18F]PARPi
(i.v.) alone, or with a previous injection of talazoparib (0.3 mg/kg) or olaparib (50mg/kg) 30min prior to [18F]PARPi. Tumor (top) and muscle (bottom)
were collected 2 h post [18F]PARPi injection, sectioned and either exposed overnight (autoradiography), stained with H&E or stained for PARP1. Example
images are shown for a [18F]PARPi alone, b [18F]PARPi with a prior injection of talazoparib and c [18F]PARPi with a prior injection of olaparib. d Higher
magnification of PARP1 IHC of a tumor and muscle sample. e Quantification of autoradiography signal and PARP1 expression. Non-parametric Student’s t-
test was used to calculate the statistics. ****P< 0.0001. Displayed data represent means with SD from three sections of three tumors/group
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45% (Fig. 6e). A significant reduction of [18F]PARPi was also
observed in muscle tissue, despite the low PARP1 expression.
Target engagement differs for different PARP therapeutics.
Since we saw that talazoparib, at the therapeutic doses used
preclinically20, does not exhibit complete target engagement we
next aimed to study different doses of olaparib and talazoparib
and to correlate these doses to the level of target engagement as
shown by [18F]PARPi blocking (Fig. 7). A positive control cohort
(receiving vehicle control instead of PARP inhibitor) showed a
mean [18F]PARPi uptake of 0.87± 0.21 %ID/g.
The results for olaparib showed that the therapeutic dose level
is much higher than required to achieve near complete target
engagement. Doses of 50 mg/kg showed 78% blocking with a
mean uptake of 0.19± 0.03 %ID/g, and 15mg/kg resulted in
similar 75% blocking with a mean uptake of 0.22± 0.01 %ID/g
(P> 0.25; Fig. 7b). When we reduced the dose to 5 mg/kg we saw
a significant reduction to 59% target engagement (0.36± 0.03
%ID/g, P< 0.005), compared to the control cohort. At 1.5 mg/kg
target engagement was further reduced to 34% (0.57± 0.06
%ID/g, P< 0.001). This value is not statistically different from
the control values (P> 0.1). We fit a single-phase decay curve
(R2 = 0.8629) to this data (Fig. 7c, left) to calculate the 50%
blocking dose to be 3.17 mg/kg.
For talazoparib, the therapeutic dose was found to be
insufficient to achieve complete target engagement. Doses of
0.3 mg/kg resulted in 50% target engagement (0.44± 0.06 %ID/g
[18F]PARPi in tumor tissue). An increase of the administered
dose to 0.9 mg/kg further increased the target engagement to
64% (0.32± 0.05 %ID/g, P< 0.05). Increase in dose to 5 mg/kg
resulted in 89% target engagement (0.10± 0.02 %ID/g, P< 0.05),
while 15 mg/kg showed no further increase in target engagement
(84%, 0.14± 0.01%ID/g, P> 0.05) (Fig. 7b). A single phase decay
curve (R2 = 0.8462) (Fig. 7c, right) was used to calculate the 50%
blocking dose to be 0.36 mg/kg.
Interestingly, while target engagement was more complete for
olaparib when using doses used in preclinical therapeutic studies
(78 and 50% for olaparib and talazoparib, respectively; Fig. 7d),
talazoparib achieved a more quantitative target engagement
at similar doses (59% and 89% for olaparib and talazoparib at
5 mg/kg, respectively, 75% and 84% for olaparib and talazoparib
at 15 mg/kg, respectively; Fig. 7d).
[18F]PARPi detects differences in kinetic properties in vivo.
The dosing studies showed a significant difference between ola-
parib and talazoparib in their ability to block [18F]PARPi signal
in the tumor at a single defined time point. An important factor
in measuring the deposited effective doses, however, is how long
the inhibitor occupies the binding site. Therefore we sought to
determine the residence time of olaparib and talazoparib in vivo.
We conducted experiments to measure the on-target residence













































































































































Fig. 7 Variable dose blocking. JHU-LX48 SCLC PDX bearing mice (n= 3/group, 9 groups, 27 total) were injected (i.v.) first with olaparib (0–50mg/kg) or
talazoparib (0–15 mg/kg). Mice were injected (i.v.) with 200–300 μCi of [18F]PARPi 30min later, and imaged via PET/CT 2 h later. a Representative MIPs
from 4 different doses each, for olaparib (left) and talazoparib (right). b Quantification of PET images for tumor uptake at each of 4 different doses of
olaparib (left) and talazoparib (right), compared to [18F]PARPi only. c Curve fitting analysis for olaparib (left) and talazoparib (right) showing calculated
50% blocking doses. d Comparison of olaparib and talazoparib at equal doses (left) and at therapeutic doses (right). Non-parametric Student’s t-test was
used to calculate the statistics. *P< 0.05; **P< 0.01. Error bars represent the SD
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between administration of the drug and administration of the
tracer (Fig. 8a). For olaparib, we found that, at 50 mg/kg, an
initial scan showed 74% target engagement (0.24± 0.00 %ID/g) at
60 min between injection of olaparib and [18F]PARPi. Mice with
longer time intervals between injection of drug and tracer showed
gradual increase in [18F]PARPi signal (Fig. 8b, top) until, at 48 h,
we measured tumor uptake to be 0.88± 0.15 %ID/g, which
was not statistically different from the control cohort of mice
which did not receive olaparib. We fit a two phase decay curve
(R2 = 0.8548) to the target engagement data and used this to
calculate a weighted half-life of 9.4 h (Fig. 8c, left). This number
represents the amount of time it took for half of the [18F]PARPi
signal in the tumor to return after a (therapeutic) dose of
50 mg/kg olaparib. We also used this curve to calculate an area
under the curve, which was 1078 %h for olaparib. This number is
a measure for the target engagement of a single dose of olaparib
(50 mg/kg) over 48 h. Complete 100% target engagement over
48 h would result in an integral of 4800 %h.
We repeated this procedure for talazoparib and found that, at
0.3 mg/kg, the 60 min time point showed 0.40± 0.02 %ID/g with
56% target engagement. Again, we found a gradual increase in
[18F]PARPi signal as we increased the interval between drug and
tracer (Fig. 8b, right). At 48 h, we measured 0.82± 0.18 %ID/g,
which was not statistically different from the control cohort of
mice which did not receive talazoparib. We fit a two phase decay
curve (R2 = 0.6328) to the target engagement data and used this to
calculate a weighted half-life of 9.8 h (Fig. 8c, right). This number
represents the amount of time it took for half of the [18F]PARPi
signal in the tumor to return after a dose of 0.3 mg/kg talazoparib.
We also used this curve to calculate an area under the curve,
which was 1021 %h. This number represents the total amount of
[18F]PARPi signal blocking a single dose of 0.3 mg/kg talazoparib
provides over the course of 48 h.
Hence, we found comparable tumor residence times for
olaparib and talazoparib, despite differences in the applied dose,
differences in the initial target engagement and reported
differences in affinity and trapping potential (Table 2).
Discussion
In this study, we demonstrated the feasibility of quantitative
in vivo target engagement of a family of PARP inhibitors in SCLC
PDX models using a molecularly targeted PET imaging agent. An











































Fig. 8 In vivo kinetics of different PARP inhibitors. a JHU-LX48 SCLC PDX bearing mice (n= 3/group, 15 groups, 45 mice total) were injected (i.v.) first with
olaparib (50mg/kg) or talazoparib (0.3 mg/kg). Mice were injected (i.v.) with 200–300 µCi of [18F]PARPi 1, 2, 4, 8, 24, or 48 h later, and imaged via PET/
CT 2 h post [18F]PARPi injection. b Representative coronal slices from 4 different time points after olaparib (left) and talazoparib (right) administration. c
Quantification of PET images for tumor uptake at each of 6 different time points represented as a percentage of blocked signal. Error bars represent the SD
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for PARP inhibitor treatment planning and monitoring in the
clinic.
Currently, there are several, molecularly targeted PARP
therapeutics which are being tested in the clinic. Despite the
universal importance of PARP for DNA repair, response to PARP
inhibitor treatment can vary dramatically between patients. This
observation has prompted a number of investigations aimed at
determining biomarkers for PARP inhibitor treatment. These
studies have identified deficiencies in other DNA repair pathways,
such as BRCA1/221,22 or expression of SLFN1123,24, as important
factors that increase tumor cell sensitivity to PARP inhibition. We
expect that within genetically similar patient cohorts, however,
sufficient target expression, drug delivery and target engagement
are likely to be foundational pillars for effective PARP inhibitor
treatment. Invasive tumor biopsy has some utility in assessing
target expression, but a small core sample of a single lesion will
not capture tumor heterogeneity of expression and cannot pro-
vide insight into the dynamics of target engagement and drug
delivery. It is currently not possible to measure if PARP inhibitor
intratumoral delivery, target engagement and duration of target
suppression are sufficient to elicit a response. Such data could
provide a faster feedback and uniquely valuable information in
planning and adapting treatment regimens.
The need for such approaches has recently been underlined by
the failure of iniparib. Iniparib was believed to be a PARP inhi-
bitor16,17 but failed in a phase III clinical trial when it was realized
that iniparib does not actually inhibit PARP. The inability of
iniparib to block binding of PARPi-FL was immediately evident
using our assay, and could have informed decisions early in its
development, even prior to clinical testing.
Interestingly, our in vitro data suggests that different PARP
inhibitors have varying residence times in tumor cells. This
variable could contribute to the diverse treatment efficacies that
have been observed25. Intracellular residence times could repre-
sent an additional measurement in evaluating PARP inhibitor
efficacy in addition to IC50s and PARP trapping14.
We have shown that our fluorescently labeled and 18F-labeled
PARP imaging probes are capable of quantifying PARP inhibitor
target engagement. Both showed high specificity for PARP1 and
PARP2, key members of the PARP enzyme family. Our study,
which measured enzymatic activity at 100 nM of inhibitor, differs
methodologically from a previous study which utilized differential
scanning fluorimetry (DSF) to produce cross family reactivity
profiles7, but yielded generally similar binding profiles for ola-
parib, veliparib, and rucaparib with respect to PARP1–3. Both
imaging agents showed selective inhibition for PARP1/2 while
showing less inhibition for PARP3. This is somewhat surprising
given that both imaging agents contain a 1-(2 H)-phthalazinone,
pharmacophore similar to olaparib, which shows inhibition of
PARP3. Because of their exceptional selectivity and strong
binding profile, our imaging agents were indeed able to quanti-
tatively determine target engagement across the entire class of
clinically active PARP inhibitors. We have shown that PARPi-FL
can image target engagement for five clinical inhibitors currently
either in phase III trials or FDA approved. We have also shown
that [18F]PARPi can be used to detect target engagement for
olaparib and talazoparib, both therapeutic inhibitors which are of
special interest for SCLC6,23. Importantly, the imaging agents
were capable of determining both partial target engagement as
well as complete target engagement. Identification of incomplete
target engagement with a radiolabeled PARP imaging agent in a
clinical treatment setting could potentially allow for adjustments
of the PARP inhibitor dose to avoid underdosing and, therefore,
increase the likelihood of therapeutic success. This type of ima-
ging could be performed before, after and during a treatment
cycle, because, for [18F]PARPi (0.97 Ci/μmol), only about 10 μg of
material needs be injected to obtain good signal/noise ratios in a
PET/CT scanner (10 mCi/patient) whereas therapeutics are
administered in much higher quantities. Currently, human dosing
for olaparib is 600 mg per day (300 mg twice daily,
NCT02032823, NCT02184195), and even talazoparib is being
tested at 1 mg per day (NCT01945775). This indicates that an
injection of [18F]PARPi is a tracer dose, 100 times less than the
daily dose of talazoparib and 60,000 times less than that of
olaparib.
Characterization of olaparib and talazoparib using [18F]PARPi
PET quantitatively illustrated the differences between the two
PARP inhibitors. We found that doses previously used to provide
therapeutic effects in the preclinical setting (50 mg/kg for ola-
parib, 0.3 mg/kg for talazoparib)26,27 are higher than necessary
for olaparib and lower than necessary for talazoparib to provide
complete saturation of the available binding sites at the tumor.
This might lend credence to the preclinical evidence that the two
drugs offer efficacy that varies with potency of different
mechanisms (PARP inhibition vs. PARP trapping)28. Our kinetic
studies showed that a slightly faster dissociation for olaparib
resulted in a very similar overall effective dose as measured by
integrating the occupation of the binding sites over the course of
48 h, and that this value (Fig. 8c) might be a valuable pharma-
codynamic parameter.
In summary, the molecular imaging oriented approach to drug
characterization and target engagement measurement presented
here provides a robust and adaptable method for answering
important questions regarding the interaction of a targeted drug
with its intended binding site in a quantifiable manner in vitro
and in vivo. Imaging techniques like this have the potential not
only to revolutionize the way that drugs are prepared but also
used in the clinic, and could pave the way for more robust and
successful patient selection and treatment monitoring. More
specifically, our PET imaging agent [18F]PARPi might be used to
quantify target engagement of phase III and FDA approved
PARP1 inhibitors in vivo without the need of creating individual
companion imaging agents for each drug. This non-invasive,
whole body approach could potentially preclude the need for
multiple temporally and spatially separated biopsies, and would
allow quantification of target engagement for each lesion in an
individual. [18F]PARPi PET may provide a robust tool for
treatment and patient selection with profound clinical-
translational implications.
Methods
General. High performance liquid chromatography (HPLC) purification and
analysis was performed on a Shimadzu UFLC HPLC system equipped with a
DGU-20A degasser, a SPD-M20A UV detector, a LC-20AB pump system, and a
CBM-20A communication BUS module. A LabLogic Scan-RAM radio-TLC/
HPLC-detector was used for the radioactive signal. HPLC solvents (Buffer A: 0.1%
TFA in water, Buffer B: 0.1% TFA in MeCN) were filtered before use. HPLC
purification was performed on a semi-prep reversed phase Phenomenex Gemini
column (C6-Phenyl, 5 μm, 10 mm, and 250 mm) while analysis was performed on
an analytical reversed phase Phenomenex Gemini column (C18, 5 μm, 4.6 mm, and
250 mm). Purification was performed with Method A (flowrate: 5 mL/min; iso-
cratic: 0–45 min 30% B). Analysis was performed with Method B (flowrate: 1.5 mL/
min; gradient: 0–14 min 5–100% B; 14–18 min 100% B; 18–18.5 min
Table 2 Summary of in vivo kinetics data of olaparib and
talazoparib
Initial blocking (t= 1 h) t1/2 (weighted) AUC
Olaparib 74% 9.4 h 1078 %h
Talazoparib 56% 9.8 h 1021 %h
RatioT:O 0.76 1.04 0.95
In vivo kinetics measurements
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100%-5% B; 18.5–22 min 5% B). All PET imaging experiments were conducted on
a microPET INVEON camera equipped with a CT scanner (Siemens, Knoxville,
TN). Digital phosphor autoradiography was obtained using a Typhoon FLA 7000
laser scanner from GE Healthcare (Port Washington, NY).
Chemicals. Commercially available compounds were used without further pur-
ification unless otherwise stated. 4,7,13,16,21,24-Hexaoxa-1,10-diazabicyclo[8.8.8]
hexacosane (K222), extra dry dimethyl sulfoxide (DMSO) over molecular sieves,
Ethyl 4-nitrobenzoate, and 4-Fluorobenzoic acid were purchased from Sigma-
Aldrich (St. Louis, MO). Water (>18.2 MΩcm-1 at 25 °C) was obtained from an
Alpha-Q Ultrapure water system from Millipore (Bedford, MA). Commercially
available PARP inhibitors were purchased through SelleckChem. PARP inhibitors
were kept as 10 mM stock solutions in DMSO and diluted to the final working
concentration for the respective in vitro experiment with full medium.
PARPi-FL synthesis. The green fluorescent dye BODIPY-FL NHS-ester (Invitro-
gen, Carlsbad, CA) was conjugated to 4-(4-fluoro-3-(piperazine-1-carbonyl)benzyl)
phthalazin-1(2H)-one and purified by preparative HPLC (Waters’ XTerra C-18 5
μm column, 7 mL/min, 5 to 95% of acetonitrile in 15 min) to afford PARPi-FL in
70–79% yield as a red solid. Analytical HPLC analysis (Waters’ Atlantis T3 C18
5 μm 4.6 × 250 mm column) showed high purity (>97%) of the imaging agent.
The identity of PARPi-FL was confirmed using ESI-MS (MS(+) m/z = 663.4
[M + Na]+).
19F-PARPi synthesis. 4-(4-fluoro-3-(piperazine-1-carbonyl)benzyl)phthalazin- 1
(2H)-one was dissolved in MeCN and 4-fluorobenzoic acid was added followed by
N,N,N’,N’-Tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate
(HBTU) and Et3N. The reaction mixture was stirred for 5 min and purified by
preparative HPLC (Waters’ XTerra C-18 5 μm column, 7 mL/min, 5 to 95% of
acetonitrile in 15 min) to produce the compound in 40–50% yield as a white solid.
Analytical HPLC analysis (Waters’ Atlantis T3 C18 5 μm 4.6 × 250 mm column)
showed high purity (>97%) and the identity was confirmed using ESI-MS
(MS(+) m/z = 511.2 [M + Na]+).
Radiosynthesis. [18F]PARPi was synthesized using an optimized labeling proce-
dure. No-carrier-added (n.c.a.) [18F]fluoride was obtained via the 18O(p,n)18F
nuclear reaction of 16.5-MeV protons in an GE Healthcare PETTrace 800 using
enriched 18O-water. QMA light ion-exchange cartridges and C-18 light Sep-Pak
cartridges were obtained from Waters (Milford, MA). A QMA cartridge containing
cyclotron-produced [18F] fluoride ion (50 mCi, 1.85 GBq) was eluted with a
solution containing 9 mg Kryptofix [2.2.2] (4,7,13,16,21,24-hexaoxa-1,10-diazabi-
cyclo[8.8.8]hexacosane), 0.08 mL 0.15 M K2CO3 and 1.92 mL MeCN into a 5 mL
reaction vial. Solvents were removed azeotropically at 120 °C under N2. Afterwards,
500 µg of ethyl 4-nitrobenzoate in 100 µL of dry DMSO was added and the mixture
was heated to 150 °C for 15 min. 50 µL of 1 M NaOH was then added followed by
50 µL of 1M HCl. Then, 2 mg of 4-(4-fluoro-3-(piperazine-1-carbonyl)benzyl)
phthalazin-1(2H)-one in 100 µL of dry DMSO was added followed by 10 mg of
HBTU dissolved in 100 µL of DMSO and 20 µL of Et3N. 400 µL of MeCN and 1mL
H2O were then added to the mixture and the product was purified by HPLC
(Method A, tR = 32 min) yielding (n.d.c) 38.4 ± 2.5% with a SA of 0.97 Ci/µmol.
PARP family binding assay. Assay was performed by BPS Bioscience, San Diego,
CA. 100 µM DMSO solutions of each inhibitor were provided, and the assay was
conducted after dilution to 100, 50, or 10 nM. The measurements for each enzyme
combined with each inhibitor was performed in triplicate according the BPS assay
kit protocols. Luminescence was measured using a BioTek Synergy 2 microplate
reader. Data was reported by BPS as % Enzyme Activity. Triplicates were combined
to get a mean± SD, and these were grouped and plotted onto a heatmap using
Prism 7.
PARP1 and PARP2 IC50s. Assays were performed by BPS Bioscience, San Diego,
CA. 100 µM DMSO solutions of 19F-PARPi, PARPi-FL, and rucaparib were pro-
vided to BPS and other inhibitors were provided by BPS. Each measurement was
performed in triplicate according the BPS assay kit protocols. Luminescence was
measured using a BioTek Synergy 2 microplate reader. Data was reported by BPS
a`s % enzyme activity curve from 0.03 nM or 0.1 nM to 1000 nM.
PARylation inhibition assay. LX22 cells (5 × 106 cells/sample) were treated with
0.1 µM or 1 µM PARPi-FL, [18F]PARPi or olaparib in medium for 30 min at 37 °C
or left untreated. Whole cell lysates were prepared by incubating cells with RIPA
Buffer with Triton X (BP-140, Boston BioProducts) containing Protease Inhibitor
(Complete EASYpacks, Sigma-Aldrich) for 30 min on ice, followed by 30 min
centrifugation at 10,000 × g for 30 min at 4 °C. Protein concentration of lysates was
determined using a Bicinchoninic acid (BCA) assay kit (#23225, Pierce) and fol-
lowing the manufacturers instructions. SDS gel electrophoresis and immunoblot-
ting were carried out following standard procedures. Signal detection was carried
out using chemiluminescent substrate (#34077, Thermo Scientific). Densitometric
analysis of western blots was carried out using ImageJ (NIH). To detect PAR, we
used a rabbit polyclonal anti-PAR polymer antibody (1:1000 dilution, #4336-BPC-
100, Trevigen) followed by a goat anti-rabbit IgG-HRP secondary antibody
(1:10,000 dilution, sc-2004, SantaCruz). B-actin was used as loading control (1:1000
dilution, A3854, Sigma-Aldrich) and was stained after stripping the blot for 30 min
at room temperature using stripping buffer (Amresco).
Tissue microarray and PARP1 immunohistochemistry. PARP1 Immunohis-
tochemistry staining was carried out on tissue microarrays of PDX models of
SCLC, which were assembled from standard formalin-fixed paraffin embedded
(FFPE) PDX tissue blocks. Briefly, after antigen retrieval and blocking, sections
were incubated with anti-PARP1 primary antibody for 5 h (1:10,000; 0.02 µg/mL;
0.2 µg/mL; sc-7150, Santa Cruz Biotechnology; The antibody used for
PARP1 staining was since discontinued. Santa Cruz now offers the monoclonal
anti-PARP1 antibody [sc-8007], which we validated for PARP1 staining at a
concentration of 0.4 µg/mL), followed by 1 h with biotinylated goat anti-rabbit IgG
(PK6106, Vector Labs). For detection, a DAB detection kit (Ventana Medical
Systems) was used according to the manufacturer’s instructions. Sections were
counterstained with hematoxylin and cover-slipped with Permount (Fisher Sci-
entific). Staining was carried out using the automated Discovery XT processor
(Ventana Medical Systems) at the Molecular Cytology Core Facility at MSK. Tissue
microarrays were digitalized using a MIRAX Slide Scanner (3DHISTECH). For
PARP1 protein quantification, we calculated the PARP1-positive area for each
tissue core using MetaMorph Software (Molecular Devices, Sunnyvale, CA).
Thresholding was performed on brown (PARP1) and blue (tissue) areas and the
relative PARP1-positive area was calculated by dividing the brown area by the total
tissue area. For each PDX line, three cores of three separate animals were available
(up to nine total). If more than 50% of the area was necrotic, the core was excluded.
For each line, we evaluated at least four different cores.
Fluorescence microscopy. We conducted confocal laser scanning microscopy to
visualize the extent of intracellular blocking of PARPi-FL uptake by different
PARPi. Therefore, JHU-LX22 cells were seeded into 8-Well Chamber Slides
(Millipore) at a density of 20,000 cells per well and allowed to attach for 24 h at
37 °C. Then, cells were incubated with 0.5 µM olaparib, talazoparib, rucaparib,
veliparib, niraparib, 19F-PARPi or medium for 25 min, followed by a wash with
medium. Then, 0.5 µM PARPi-FL were added to all wells, except the unstained
control and incubated for 15 min at 37 °C. The incubation time of PARPi-FL was
within the range of linear uptake (Supplementary Fig. 9). PARPi-FL was removed
and cells were washed in fresh medium for 10 min. Next, cells were treated with 4%
Paraformaldehyde (PFA) for 8 min on ice to ensure fixation. After a final wash with
PBS, chambers were removed and slides were mounted with Mowiol mounting
medium containing Hoechst 33342 for counterstaining of nuclei. Fluorescence was
analyzed using a Leica SP5 upright confocal microscope (Leica, Buffalo Grove, IL)
equipped with appropriate laser excitation (Hoechst: 405 nm and PARPi-FL: 488
nm) and matched emission filters. PARPi-FL intensity was determined by mea-
suring the PARPi-FL fluorescence intensity in all nuclei, which were thresholded
using Hoechst staining. The measured fluorescence intensities were averaged
over 3 fields of view per experimental condition, which contained on average
144± 63 nuclei and reported as relative mean fluorescence intensities (rMFI),
where PARPi-FL uptake without blocking was defined as 100%.
Flow cytometry. For all flow cytometry experiments, 200,000 JHU-LX22 cells were
seeded into 6-Well plates and allowed to attach for 24 h. After the respective
treatment/staining, which is described below for the different experiments, cells
were washed in PBS, trypsinized, washed with flow buffer (1% BSA (w/v) in PBS),
transferred to 5 mL flow cytometry tubes through the 40 µm cell strainer cap and
left on ice until measurement in the flow cytometer (Fortessa II). Raw data were
processed in FlowJo software in order to calculate PARPi-FL uptake per cell. Dead
cells were excluded by eliminating DAPI positive cells from the analysis (Supple-
mentary Fig. 8). Cell clumps and debris were eliminated using the corresponding
gates (forward and side scatter) for the unstained cell population. PARPi-FL
fluorescence was imaged in the FITC channel against side scatter (area).
Target recovery-washing. We compared how the recovery of PARPi-FL binding
changed depending on washing regimes. Therefore, JHU-LX22 cells were incu-
bated with one of five PARP inhibitors (olaparib, talazoparib, rucaparib, veliparib,
niraparib) at a concentration of 0.2 µM for 25 min at 37 °C and washed. Then, fresh
media was added for a post-incubation time of 0, 12, 24, or 48 h. Cells were either
left in the same medium for the entire post-incubation time or additional media
exchanges were performed after 6, 20, and 40 h. Subsequently, cells were incubated
with 0.2 µM PARPi-FL for 15 min at 37 °C, followed by 10 min wash with medium
to allow unbound compound to diffuse out of the cells. Then, cells were subjected
to flow cytometry as described above.
Target recovery-dilution. Here, we compared how the recovery of PARPi-FL
binding depends on the applied PARPi concentration. JHU-LX22 cells were
incubated with one of five PARP inhibitors (olaparib, talazoparib, rucaparib,
veliparib, and niraparib) at a concentration of 0.02, 0,1, 0,2, 2, 5, or 12.5 µM for
25 min at 37 °C, washed and supplied with fresh media for the post incubation time
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of 2 or 24 h. Then, cells were incubated with 0.2 µM PARPi-FL for 15 min at 37 °C,
followed by 10 min wash with medium and subjected to flow cytometry as
described above.
PARPi-FL uptake kinetics. The experiment was conducted as described in “Flow
Cytometry” in the Methods section. The staining in this experiment consisted of
incubation of the JHU-LX22 cells with 0.2 µM PARPi-FL for 1, 2, 5, 10, 20, 30, 45,
60 or 120 min.
Competition kinetics. To confirm that the measured in vitro kinetics depend on
target engagement and did not merely reflect differences in affinity of the different
PARP inhibitors, we tested if the release of PARP inhibitors from the cells was
faster in presence of PARPi-FL and vice versa. Therefore, we incubated JHU-LX22
cells first with a PARPi (olaparib, talazoparib, rucaparib, veliparib, niraparib, and
niraparib) in a concentration of 0.2 µM or medium (control) for 20 min at 37 °C,
followed by a brief wash in media and an incubation with 0.2 µM PARPi-FL for 20,
60, or 120 min followed by 10 min wash with medium before cells were subjected to
flow cytometry as described above. To show it is more important which molecule
bound first instead of which has the higher affinity we also inverted the incubation
scheme and incubated the JHU-LX22 cells first with 0.2 µM PARPi-FL for 20 min,
followed by 0.2 µM of a PARPi (olaparib, talazoparib, rucaparib, veliparib, nir-
aparib) or medium (control) for 20 min at 37 °C, followed by a 10 min media wash
before cells were processed for flow cytometry. Controls (cells incubated with
medium instead of a PARP inhibitor) served as reference value and their PARPi-FL
signal was defined as 100%.
Cytotoxicity. Here, we aimed to measure cytotoxic effects of the PARPi (olaparib,
talazoparib, rucaparib, veliparib, and niraparib) and imaging compounds (PARPi-
FL, 19F-PARPi) on JHU-LX22 cells using the Alamar Blue assay (Invitrogen). Cells
were plated in 96-well plates (black, clear-bottom, Corning Incorporated) at a
density of 5,000 cells/well and allowed them to attach for 24 h. All compounds were
prepared as 10 mM stock solutions in DMSO and further diluted in media. Cells
were treated with 0, 2, 5, and 10 µM (final solutions containing 1% DMSO) of each
compound for 24, 48, 72 and 96 h. Then, media was removed and Alamar Blue
reagent was added to each well. Plates were incubated at 37 °C for 4 h under
protection from direct light. Fluorescence was read (bottom-read mode) using an
excitation wavelength of 570 nm and an emission wavelength of 585 nm on a
SpectraMax M5 microplate reader (Molecular Devices, Sunnyvale, CA, USA). The
average reading values were analyzed by subtracting the background readings
(wells with Alamar Blue but without cells) and compared against the untreated
controls of each plate (defined as 100% viability) to determine the percentage of
living cells. The experiment was carried out in three biological replicates with four
parallels of each compound. The displayed data represent means and standard
errors.
Extent of PARPi-FL blocking by various PARPi. To quantify the extent of
blocking of PARPi-FL uptake by different PARPi, we quantified the intracellular
PARPi-FL uptake in JHU-LX22 cells after incubation with PARP inhibitors.
Therefore, PARPi (olaparib, talazoparib, rucaparib, veliparib, niraparib, and
19F-PARPi) were added to wells at a concentration of 0.2 µM for 25 min at 37 °C.
After a brief wash with medium, cells were incubated with 0.2 µM PARPi-FL for
15 min at 37 °C and washed for 10 min in medium, followed by the flow cytometry
protocol described above.
In vitro Kinetics. We furthermore determined the duration of PARPi binding to
their target site. Therefore, JHU-LX22 cells were incubated with one of five PARP
inhibitors (olaparib, talazoparib, rucaparib, veliparib, niraparib, or 19F-PARPi) at a
concentration of 0.2 µM for 25 min at 37 °C and washed. Then, fresh media was
added for a post-incubation time of 0, 1, 2, 4, 8, 12, 24, or 48 h. Subsequently, cells
were incubated with 0.2 µM PARPi-FL for 15 min at 37 °C, followed by 10 min
wash with medium to allow unbound compound to diffuse out of the cells. Then,
cells were subjected to flow cytometry as described above. Cells that have not been
exposed to a PARP inhibitor served as control, and were defined as 0% relative
PARP inhibition. We determined the duration of binding of the PARPi indirectly
by calculating the recovery of PARP-FL binding with increasing times between
PARPi and PARPi-FL treatment. Decay curves were calculated with Prism using
two phase decay least squares regression.
Animals. We used 12 nude and 24 NSG mice for biodistribution, and 96 NSG mice
for imaging experiments. Female athymic nude CrTac:NCr-Foxn1nu mice at age
6–8 weeks were purchased from Taconic Laboratories (Hudson, NY). Female NSG
mice (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ; The Jackson Laboratory) were 6 to
8 weeks old at time of PDX injection/implantation. All animal experiments were
done in accordance with protocols approved by the Institutional Animal Care and
Use Committee (IACUC) of Memorial Sloan Kettering Cancer Center (MSKCC)
and followed the National Institutes of Health guidelines for animal welfare.
SCLC PDX Models. PDX lines were derived at Johns Hopkins University from
patients with extensive stage SCLC31,32. After PDX model establishment, tumors
were serial passaged and expanded into 6-week-old to 8-week-old female NSG
mice. To establish experimental cohorts, ~ 300 mg of fresh tumor tissue was dis-
sociated into single cell suspension in 5 mL of RPMI 1640 supplemented with
human tumor dissociation enzyme kit in a gentleMACS C tube using an octo-
MACS automated tissue dissociator (Miltenyi). 5 × 106 viable cells/mouse were
injected with a 1:1 mix of Hank’s balanced salt solution and Matrigel basement
membrane (Corning) in a final volume of 100 μL subcutaneously into the right
shoulder. PDX identity was confirmed by Short Tandem Repeat analysis using the
PowerPlex 18 panel (Promega, Madison, WI, USA; DDC Medical is Fairfield, OH,
USA). Because of the lines’ inherent varying preferences to grow in vitro/propagate
in vivo, we chose LX22 for all in vitro experiments, whereas LX48 was chosen for
in vivo experiments. All animal experiments were approved by the Institutional
Animal Care and Use Committee (IACUC) of Memorial Sloan Kettering Cancer
Center.
Biodistribution. Healthy nude (n = 6/group, 2 groups, 12 total), healthy NSG
(n = 6/group, 2 groups, 12 total), or tumor bearing NSG (n = 6/group, 2 groups,
12 total) mice were injected either with or olaparib as a blocking agent (50 mg/kg)
30 min prior to injections of 200–300 μCi of [18F]PARPi in 100–200 μL 10% EtOH
in 0.9% sterile saline. Animals were sacrificed at 2 h post injection of the radioactive
probe, and major organs were collected, weighed, and counted in a Wizard2
automatic γ-counter (PerkinElmer, Boston, MA). The radiopharmaceutical uptake
was expressed as a percentage of injected dose per gram (%ID/g) using the
following formula: [(activity in the target organ/grams of tissue)/injected dose] ×
100%.
General PET/CT Imaging. All PET/CT images (n = 90) were acquired on an
Inveon PET/CT (Siemens) and reconstructed scans were analyzed using the Inveon
Research Workplace Software (Siemens). To acquire PET/CT images, animals were
anesthetized with 2% isoflurane and positioned on the scanner bed. Animals were
intravenously injected with 200–300 µCi of [18F]PARPi in 100–200 μL 10% EtOH
in 0.9% sterile saline. Except for the determination of tracer kinetics, [18F]PARPi
was allowed to clear for 2 h prior to PET/CT imaging. PET data were collected for
5–10 min, followed by CT.
PET/CT imaging agent kinetics. JHU-LX48 SCLC PDX tumor bearing NSG mice
(n = 3/group, 3 groups, 9 mice total) were administered 200–300 µCi of [18F]PARPi
and imaged at 30, 60, or 120 min post injection. Different mice were used for each
group to eliminate, as much as possible, the influence of anesthesia on tracer
distribution. Activity concentration was quantified by averaging the mean values
taken from VOIs drawn on the chosen organs as they appeared in the CT and
reported as a mean %ID/g ± SD.
PET/CT tumor size study. JHU-LX48 SCLC PDX cells where implanted into NSG
mice (n = 6 mice) 7 days prior to the first imaging. [18F]PARPi PET/CT imaging
was carried on the day of tumor implantation and once every 7 days thereafter.
This was continued for 8 consecutive weeks until mice were sacrificed to avoid
surpassing a tumor size limit of 1500 mm3. Activity concentration was quantified
by averaging the mean or max values taken from VOIs drawn over the entire
tumor as it appeared in the CT and portrayed as mean and max %ID/g± SD.
PET/CT dosing study. JHU-LX48 SCLC PDX tumor bearing mice (n = 3/group,
9 groups, 27 mice total) were administered varying doses of a therapeutic inhibitor
via tail vein injection to serve as blocking agents prior to imaging. The doses
administered for olaparib were 50mg/kg, 15mg/kg, 5mg/kg and 1.5 mg/kg. The
doses administered for talazoparib were 15mg/kg, 5 mg/kg, 0.5mg/kg and 0.3mg/kg.
The control group received no therapeutic inhibitor. [18F]PARPi was administered
30 min after the blocking doses and imaging was performed as described above.
Activity concentration was quantified by averaging the mean values taken from
VOIs drawn over the entire tumor as it appeared in the CT and portrayed as a
mean %ID/g± SD.
In vivo kinetics. JHU-LX48 SCLC PDX tumor bearing mice (n = 3/group, 15
groups, 45 mice total) were administered therapeutic doses of olaparib (50 mg/kg)
or talazoparib (0.3 mg/kg) via tail vein injection to serve as blocking agents prior to
imaging. The amount of time in between administration of the blocking agent and
tracer was 1, 2, 4, 8, 24, or 48 h. After allowing this clearance time for the blocking
agent, the imaging was performed as described above. Activity concentration was
quantified by averaging the mean values taken from VOIs drawn over the entire
tumor as it appeared in the CT and portrayed as a mean %ID/g± SD.
Autoradiography. JHU-LX48 SCLC PDX tumor bearing mice (n = 3/group, 3
groups, 9 mice total) were injected either with 200–300 μCi of [18F]PARPi (i.v.)
alone, or with a previous injection of talazoparib (0.3 mg/kg) or olaparib (50 mg/
kg) 30 min prior to [18F]PARPi. 2 h post [18F]PARPi injection, mice were sacrificed
and tumor and muscle were resected, immediately frozen in OCT compound and
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10 µm cryosections were prepared using a cryotome. Sections from 3 different
tumor areas from each tumor (n = 3/group) were exposed to an autoradiography
plate overnight and read the next day. ImageJ was used to quantify the signal
intensity of each tissue. Adjacent sections were used for PARP1 IHC and H&E
staining to confirm tissue identity and PARP1 expression.
Statistical analysis. Data are expressed as mean± SD. Statistical analyses were
performed with GraphPad Prism, Version 7.0a (La Jolla, CA). Non-parametric,
two-tailed Student’s t-tests with assumption of unequal standard deviations were
used to calculate statistics. P-values< 0.05 were considered significant.
Data availability. All the data supporting the findings of this study are available
within the article and its supplementary information files or from the corre-
sponding author upon reasonable request.
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